In Vivo Evaluation of 5-Fluorouracil-Containing Self-Expandable Nitinol Stent in Rabbits: Efficiency in Long-Term Local Drug Delivery

Paclitaxel or 5-fluorouracil/esophageal stent combinations as a novel approach for the treatment of esophageal cancer

“…The drug/stent combination was prepared based on a previous study [10]. Briefly, a fully blended mixture of drug particles and melted ethylene-vinyl acetate (EVA) (drug: EVA ¼ 1:1, w/w) was compressed into films (each with a uniform thickness of 300 mm) after exposure to a heat source.…”

A highly flexible paclitaxel-loaded poly(ε-caprolactone) electrospun fibrous-membrane-covered stent for benign cardia stricture

“…Some studies of coating technologies for esophageal stents are presently available for laboratory and clinical applications. Guo et al reported that ethylene-vinyl acetate (EVA) film containing 5-fluorouracil (5-FU) was coated and agglutinated on esophageal stent by hot-pressing [13,14], which could release the 5-FU in a sustained pattern for a prolonged time, achieving high 5-FU bioavailability near the site of action, and thus alleviating restenosis. Jeon et al coated paclitaxel-silicone on the metal esophageal stents through casting film, and animal results showed very little tissue reaction and hyperplasia [1].…”

Drug-eluting/biodegradable stents

“…36 In vitro and in vivo studies (the latter using drug-coated SEMSs) have demonstrated that local exposure to paclitaxel, 5-fluorouracil, and gemcitabine can induce local responses when placed in contact with both benign and malignant GI tract tissues. [37][38][39][40][41][42][43][44] To date, there are only a few small published case series in humans. These demonstrated that partial responses in unresectable cholangiocarcinoma can be achieved with a carboplatincoated percutaneous biliary tube, 45 and endoscopically placed drug-eluting SEMS may be associated with improved stent patency and overall survival in patients with extrahepatic cholangiocarcinoma.…”